February 26th 2024
The ANX007 global pivotal program is the first to use vision preservation as a primary outcome measure in GA.
Pegcetacoplan shows increasing beneficial effects after 30 months of continuous treatment for GA
August 2nd 2023Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).